CeriBell (NASDAQ:CBLL) VP David Foehr Sells 5,556 Shares

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 5,556 shares of CeriBell stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $20.00, for a total value of $111,120.00. Following the sale, the vice president owned 18,900 shares in the company, valued at $378,000. This trade represents a 22.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

David Foehr also recently made the following trade(s):

• On Monday, January 5th, David Foehr sold 5,556 shares of CeriBell stock. The shares were sold at an average price of $22.60, for a total value of $125,565.60.
• On Wednesday, December 3rd, David Foehr sold 5,265 shares of CeriBell stock. The stock was sold at an average price of $16.83, for a total value of $88,609.95.

CeriBell Stock Performance

NASDAQ:CBLL traded down $0.89 on Thursday, reaching $19.27. 128,450 shares of the company’s stock were exchanged, compared to its average volume of 370,512. The stock has a fifty day simple moving average of $21.05 and a 200-day simple moving average of $15.62. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $26.04. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25. The firm has a market cap of $714.65 million, a price-to-earnings ratio of -12.76 and a beta of 1.03.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The company had revenue of $22.59 million during the quarter, compared to analysts’ expectations of $21.78 million. As a group, sell-side analysts predict that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in CeriBell in the third quarter worth $33,000. CWM LLC grew its holdings in CeriBell by 1,178.5% in the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after purchasing an additional 1,697 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after purchasing an additional 1,801 shares during the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of CeriBell by 97.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after purchasing an additional 1,256 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey increased its position in CeriBell by 161.0% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock valued at $106,000 after buying an additional 3,502 shares in the last quarter.

Analyst Ratings Changes

CBLL has been the topic of several recent analyst reports. Canaccord Genuity Group raised their price target on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Raymond James Financial initiated coverage on CeriBell in a report on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of CeriBell in a report on Wednesday, October 8th. TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a research note on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.